Establishing an Autopsy-Based Cerebrospinal Fluid Biomarker Signature in Alzheimer Disease Patients

Clin Chem. 2022 Oct 6;68(10):1336-1337. doi: 10.1093/clinchem/hvac137.

Authors

Leslie M Shaw¹, Hugo Vanderstichele², Malgorzata Knapik-Czajka³, Kaj Blennow⁴, John Q Trojanowski¹

Affiliations

¹ University of Pennsylvania Perelman School of Medicine, Department of Pathology and Laboratory Medicine, Philadelphia, PA, USA.
² Biomarkable, Gent, Belgium.
³ Jagiellonian University in Kraków Medical College, Krakow, Małopolskie, Poland.
⁴ Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg Sahlgrenska Academy, Goteborg, Sweden.

No abstract available

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Alzheimer Disease* / cerebrospinal fluid
Alzheimer Disease* / diagnosis
Amyloid beta-Peptides / cerebrospinal fluid
Autopsy
Biomarkers / cerebrospinal fluid
Humans
Peptide Fragments / cerebrospinal fluid
tau Proteins / cerebrospinal fluid

Substances

Amyloid beta-Peptides
Biomarkers
Peptide Fragments
tau Proteins

Grants and funding